MINUTES OF MEETING - June 5-6 
15 
etc. Dr. Talbot replied that the word "deleted" would be substituted for 
the current wording in Section I-D-3. 
Dr. Nightingale asked how the proposed CDC reclassification effort will 
affect the NIH Guidelines. Er. Talbot replied that the 1974 CDC Classifi- 
cation was incorporated into the NIH Guidelines and would remain in 
Appendix B until the NIH, with RAC advice, promulgates the incorporation 
of any revised classification into Appendix B. 
Dr. Krimsky asked what containment levels are used in working with Class 
3 pathogens. Dr. Young replied that most Class 3 pathogens are handled 
at the P3 equivalent level of containment. E*:. Gottesman moved acceptance 
of the language as it appeared in the Federal Register with Dr. Baltimore's 
suggested language in Section IV-E-l-b-(2)-(e) and the clause "beyond 
that which occurs by natural genetic exchange" added to Sections III and 
IV-E-l-b-(2)-(e) . The proposal was accepted by a vote of fourteen in 
favor, none opposed, and three abstentions. 
VI. CLONING OF FOOT AND MOUTH DISEASE VIRUS - STAGE II 
Dr. Baltimore began the discussion of tabs 881/9 and 888 with a brief 
review of the history of the Plum Island Animal Disease Center (PIADC)- 
Genentech, Inc., proposal. He noted that at the December 6-7, 1979 
meeting the RAC recommended approval, with certain stipulations, of 
Stage I of the PIADC-Genentech, Inc., proposal to produce a vaccine 
against Foot and Mouth Disease. Stage I work was the reverse transcrib- 
ing and cloning of segments of the Foot and Mouth Disease Virus (FMDV) 
genome at the PIADC facility at Plum Island, New York. He said the RAC 
deferred approval of Stage II, removal of the clones from Plum Island to 
the Genentech, Inc., facility in California, until the RAC reviewed 
the results of Stage I. He said PIADC-Genentech, Inc., had submitted 
data for review, and were now requesting permission to remove a collec- 
tion of clones from Plum Island. In keeping with the RAC requirement 
that the clones to be removed do not contain among them, individually or 
collectively, the entire FMDV genome, PIADC-Genentech, Inc., proposed 
removing seventeen clones containing a total of 6,000 nucleotides of the 
FMDV genome. He said PIADC-Genentech, Inc., proposes to leave at the 
Plum Island Animal Disease Center three clones containing at least 1,000 
nucleotides of the 3' end of the FMDV genome. 
Dr. Baltimore said he had two minor reservations concerning the Stage II 
proposal: (1) whether the segment of the genome to remain at Plum Island 
is absolutely necessary for infectivity, and (2) the length of the genome. 
In spite of these minor reservations, Dr. Baltimore said he felt quite 
confident that the 3' end of the genome to be left on Plum Island is 
necessary for infectivity. He suggested that if RAC required ccmplete 
reassurance they might recommend that clone pCT 196 also not be shipped 
off Plum Island. Et. Zaitlin said he felt the PIADC-Genentech, Inc., 
[ 115 ] 
